Fixed‐dose single tablet antidiabetic combinations

@article{Bailey2009FixeddoseST,
  title={Fixed‐dose single tablet antidiabetic combinations},
  author={Clifford J. Bailey and Caroline Day},
  journal={Diabetes},
  year={2009},
  volume={11}
}
Combinations of two or more oral agents with different mechanisms of action are often used for the management of hyperglycaemia in type 2 diabetes. While these combinations have customarily been taken as separate tablets, several fixed‐dose single tablet combinations are now available. These are based on bioequivalence with the separate tablets, giving similar efficacy to the separate tablets and necessitating the same cautions and contraindications that apply to each active component. Fixed… Expand
Anti-obesity fixed-dose combinations
TLDR
The management of hypertension, dyslipidaemia and hyperglycaemia often requires multiple medications that combine two or more agents with different modes of action to give additive efficacy, and single-tablet (‘fixed-dose’) combinations have been introduced to offer greater convenience. Expand
Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes
TLDR
The fixed-dose combination of pioglitazone and extended-release metformin provides a new option when implementing therapy with a well-characterized oral agent combination, and may be particularly appropriate for patients in whom adherence is a concern. Expand
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone
TLDR
The combination of sitagliptin and pioglitazone was well tolerated in these trials, and would appear to be suited to a fixed-dose single-tablet combination for once-daily administration. Expand
Saxagliptin plus metformin combination therapy
  • A. Scheen
  • Medicine
  • Expert review of endocrinology & metabolism
  • 2012
Metformin is considered to be the first-line drug therapy for the management of Type 2 diabetes. Incretin-based therapies, and especially dipeptidyl peptidase-4 inhibitors, offer new opportunitiesExpand
Fixed-dose single tablet combinations: an alternative for initial therapy of patients with Type 2 diabetes?
TLDR
It is concluded that T2D patients treated with FDCT may have better adherence, improved satisfaction, and lower direct medical costs, compared to those treated with loose-pill combination therapies, which may provide a valuable initial treatment choice to type 2 diabetes patients. Expand
Combine and conquer: advantages and disadvantages of fixed‐dose combination therapy
  • D. Bell
  • Medicine
  • Diabetes, obesity & metabolism
  • 2013
TLDR
Four key benefits are identified and discussed in support of FDCs for treatment of patients with T2DM: greater efficacy compared with higher dose monotherapy, reduced risk of adverse reactions relative to higher dosemonotherapy, lower overall costs and improved medication concordance. Expand
Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes
  • A. Scheen
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2015
TLDR
The clinical efficacy of a combined therapy is superior to any single therapy in patients treated with diet or with metformin, and combining alogliptin with pioglitazone does not alter the safety profile of each compound. Expand
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation
  • A. Scheen
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2013
TLDR
The combination linagliptin plus metformin, if not contraindicated (renal failure), may be used as first-line or second-line therapy in the management of type 2 diabetes. Expand
Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes
  • A. Scheen
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2017
TLDR
The developed saxagliptin-dapagliflozin FDC may simplify anti-hyperglycemic therapy and improve drug compliance, and pharmacodynamic observations confirm a complementary mode of action of the two agents. Expand
Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms
TLDR
An overview to pharmaceutical scientists about recent trends in the formulation development of the FDC products is given and decision trees to select most optimum formulation development strategy are provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
The development of an oralantidiabetic combination tablet: design, evaluation and clinicalbenefits for patients with type 2diabetes
TLDR
A recently-introduced metformin-glibenclamide combination tablet (Glucovancet) has been extensively studied in well-designed clinical trials, where it has been shown to be more effective than its component monotherapies in controlling fasting and postprandial glycaemia. Expand
When Antihypertensive Monotherapy Fails: Fixed-Dose Combination Therapy
  • M. Weir
  • Medicine
  • Southern medical journal
  • 2000
TLDR
Fixed-dose combination therapy is an attractive option when reasonable doses of initial antihypertensive monotherapy fail, and use of such combinations could increase patient compliance, by virtue of better tolerance compared with increased-dose monotherapy and simplicity of administration. Expand
When antihypertensive monotherapy fails: fixed-dose combination therapy.
TLDR
Fixed-dose combination therapy is an attractive option when reasonable doses of initial antihypertensive monotherapy fail, and use of such combinations could increase patient compliance, by virtue of better tolerance compared with increased-dose monotherapy and simplicity of administration. Expand
Combination therapy for type 2 diabetes.
  • S. Mudaliar, R. Henry
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 1999
TLDR
A rational approach to improvement of glycemic control in patients with type 2 diabetes mellitus with use of combination therapy is discussed, taking advantage of differing mechanisms of action in patients in whom a single agent or insulin is inadequate. Expand
Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
TLDR
The results of this retrospective database analysis suggest that rosiglitazone-metformin FDCT yielded significant improvements in medication adherence rates compared with dual therapy regimens. Expand
A fixed-dose combination of pioglitazone and metformin:a promising alternative in metabolic control
  • J. Seufert
  • Medicine
  • Current medical research and opinion
  • 2006
TLDR
The co-formulation of pioglitazone and metformin is a rational approach that maximizes the established, complimentary benefits of these agents, while potentially improving compliance and targeting glycemia, as well as other metabolic parameters. Expand
Whence and whither the fixed-dose combination?
  • C. Bailey
  • Medicine
  • Diabetes & vascular disease research
  • 2005
TLDR
Combinations of different insulins in type 1 diabetes and combinations of different oral agents in type 2 diabetes are well established, and single tablet ‘two-inone’ fixed-dose combinations are now emerging to facilitate regimens of multiple therapies. Expand
Fixed-dose combinations improve medication compliance: a meta-analysis.
TLDR
Fixed-dose combination decreases the risk of medication non-compliance and should be considered in patients with chronic conditions like hypertension for improving medication compliance which can translate into better clinical outcomes. Expand
Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
TLDR
Glipizide/metformin tablets were more effective than either glipizides or metformin monotherapy in controlling HbA1c and in reducing FPG compared with baseline in patients with blood glucose that was uncontrolled with previous sulfonylurea treatment. Expand
Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
TLDR
The benefits of fixed-dose combination rosiglitazone and MET (RSG/MET) compared with high-dose MET monotherapy in patients with type 2 DM was generally well tolerated, with the majority of AEs mild to moderate in nature. Expand
...
1
2
3
4
5
...